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Abstract
Gap junction channels permit intercellular communication through the passage of
small molecules and metabolites between adjacent cells and are involved in regulating
cellular processes such as homeostasis, differentiation, and proliferation. Connexins (Cx)
are the constituent proteins of gap junctions and the neuronal connexin, Cx36, is highly
expressed in the developing nervous system. In the present study, the effect of Cx36 on
differentiation was investigated by manipulating Cx36 expression levels and inducing
differentiation of SH-SY5Y cells. Following retinoic acid induced differentiation of SHSY5Y cells, Cx36 mRNA expression increased, while Cx45 mRNA expression was
unaffected.

Cx36 overexpression resulted in diminished retinoic acid induced

neuritogenesis, accompanied by decreased expression of differentiation markers, Gap43
and NPY, while knockdown of Cx36 had the reverse effect. Accordingly, overexpression
of Cx36 resulted in increased proliferation of SH-SY5Y cells while Cx36 knockdown
decreased cell proliferation. In conclusion, Cx36 is a transcriptional target of retinoic acid
signaling and acts as a negative regulator o f differentiation in SH-SY5Y cells.

Keywords: Cx36, Cx45, SH-SY5Y, neuroblastoma, retinoic acid, differentiation,
aggregation, proliferation
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1.1 Gap Junctions
1.1.1 Gap Junction Function
Gap junctions are important for intercellular communication and are present
within most adult mammalian cells (Sohl et al., 2005; Laird, 2006). They consist of
channels that allow electrical and chemical messaging between adjacent cells via the
passage of ions, second messengers and metabolites less than lkDa in size (Saez et al.,
1989; Goldberg et al, 1999; Alexander & Goldberg, 2003). Adenosine triphosphate,
cyclic adenosine monophosphate, and inositol triphosphate are examples of molecules
that are able to pass through gap junction channels (Goldberg et al, 1999). Within
neurons, gap junctions are responsible for the formation of bidirectional electrical
synapses, allowing synchronization of electrical activity between many cells (Connors
and Long, 2004). Gap junctional intercellular communication (GJIC) allows for the
regulation of processes such as homeostasis, cell growth, differentiation, and
synchronization (Vinken et al., 2006; Churko et al., 2010; Prost et al., 2008; lonta et al.,
2009; Omori et al., 2001).

1.1.2 Structure, Synthesis and Regulation of Gap Junctions
Connexins (Cx) are the substituent proteins of gap junction channels (Figure 1.1).
They consist of four membrane-spanning domains, 2 extracellular loops, and 3
cytoplasmic components, including a cytoplasmic loop, and amino (N)- and carboxy (C)terminals (Laird, 1996; Mese et al., 2007). The diversity of connexins arises from the
cytoplasmic loop and the C-terminus, whereas the transmembrane domains, N-terminus,
and extracellular loops are highly conserved among connexin family members (Duffy et
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al., 2002). The nomenclature of connexins is based on the predicted molecular mass of
the connexin protein; for example Cx36 is named according to its predicted molecular
mass of 36 kDa (Condorelli et al., 2000).
During the synthesis of gap junctions, connexins are co-translationally inserted
into the endoplasmic reticulum (ER) where they fold and translocate to the Golgi
apparatus. Connexins oligomerize in the Golgi to form hexamers known as connexons
(Falk et al, 1994; Musil & Goodenough, 1993). However, some connexins appear to form
hexamers in the ER rather than the Golgi (Koval, 2006). These connexons are then
transported in a closed state, within vesicles to the cell membrane. Connexons dock with
connexons of the apposing cell membrane to form gap junction channels. The channels
diffuse through the lipid bilayer to form gap junction plaques consisting of hundreds of
individual gap junction channels (Laird et al., 1995; Laird, 1996).
Connexins are dynamic and tightly regulated proteins, as indicated by their short
half-lives of 1-2 hours. This allows connexins to be rapidly trafficked to and be removed
from the cell surface depending on the metabolic needs of the cell (Laird et al., 1991;
Laird et al., 1995). Connexins associate with several binding partners, including the zona
occludins (ZO), 3 catenin, tubulin, and the cadherins, which may serve to regulate
connexin function (Toyofuku et al., 1998; Ai et al., 2000; Geipmans et al., 2001;
Geipmans et al., 2001). For example, ZO-1 acts as a chaperone to facilitate efficient
trafficking of Cx43 to the cell membrane, while N-cadherin mediates gap junction plaque
formation (Duffy et al., 2002; Wei et al., 2005). Connexins are also regulated by several
kinases, for example, the phosphorylation of Cx43 by Protein Kinase C (PKC) results in
channel closure (Solan & Lampe, 2005).
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I
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Figure 1.1. The Structure of Gap Junctions.

I

Homomeric
Heterotypic

Gap junctions are comprised of connexin subunits. Each connexin consists of 4
transmembrane domains, 2 extracellular loops, a cytoplasmic loop, and amino and
carboxy termini (A). Six connexins oligomerize to form a homomeric or heteromeric
connexon (B), which docks with a connexon from an adjacent cell to form a homotypic
or heterotypic gap junction channel (C).
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1.1.3 Connexin Expression
There are 21 known members of the connexin family in humans, and their
expression is spatially and temporally regulated. Connexin expression varies according to
cell and tissue type (Ahn et al., 2008; Brehm et al., 2007; Kihara et al., 2006). For
example, Cx36 and Cx45 are expressed in populations of mature neurons and are
responsible for electrical synapses, while Cx43 is ubiquitously expressed in tissues (Sohl
et al., 2005; Laird, 2006). Channel diversity arises from the ability of connexins to form
homomeric connexons, consisting of one connexin isoform, and heteromeric connexons,
consisting of multiple connexin isoforms (Figure 1C) (Mese et al., 2007). Gap junction
channels can also be homotypic, consisting of two identical connexons, or heterotypic,
consisting of two different connexons (Laird, 1996; Connors and Long, 2004).

1.2 Connexin 36
1.2.1 Cx36 Structure and Post Translational Modifications
Cx36 is a recently discovered connexin isoform (Condorelli et al., 1998; Sohl et
al., 1998). The human Cx36 gene is localized at the chromosomal locus 15q 14 (Belluardo
et al., 1999). Connexins are typically encoded on a single exon, however Cx36 is
structurally unique as it is encoded on two exons, interrupted by a single intron
(Belluardo et al., 1999). This places Cx36 in a novel delta subgroup of the connexin
family (Condorelli et al., 2000). The Cx36 protein consists of 321 amino acid residues,
and is characterized by a large cytoplasmic loop and short C-terminus (Figure 1.2)
(Condorelli et al., 1998; Condorelli et al., 2000; Claros & von Heijne, 1994).

6

Cx36

Figure 1.2. Topology of Cx36
Connexin36, like other connexins, consists of four transmembrane domains, 2
extracellular loops (EL), a cytoplasmic loop (CL), and intracellular amino (NH2 ) and
carboxy termini (COOH). This Cx36 structural model was created using specifications
from TopPred 2 software. Cx36 is characterized by a large cytoplasmic loop, consisting
of 111 amino acids, and a short carboxy terminus, comprised of only 51 amino acids.
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Cx36 is highly conserved between species; human and mouse Cx36 share 98% amino
acid sequence homology (Belluardo, 1999).
Interestingly, unlike Cx43, phosphorylation does not play a key role in
intracellular trafficking of Cx36, as indicated by normal plasma membrane localization
following substitution and deletion mutations at key phosphorylation sites (Zoidl et al.,
2002). Rather, the N-terminus of Cx36 is important for appropriate localization of the
protein at the plasma membrane, as seen by the aberrant cytoplasmic localization of Cx36
when the N-terminus was truncated in neuroblastoma cells (Zoidl et al., 2002).
The terminal 4 residues, or SAYV motif, of the Cx36 C-terminus also play a role
in trafficking of Cx36. When EGFP is tagged to the C-terminus of Cx36, the fusion
protein is unable to form large plaques at the plasma membrane, and has an intracellular
distribution profile (Helbig et al., 2010). The same effect is seen when the final 4 residues
of the C-terminus are truncated, thus illustrating the importance of the SAYV motif in the
trafficking of Cx36 (Helbig et al., 2010). In addition, Cx36 has been shown to interact
with scaffolding proteins, ZO-1, 2, and 3 (Li et al., 2004a, b; Li et al., 2009). The SAYV
motif is a binding site for ZO-1, which may serve as a chaperone during Cx36 trafficking
to the plasma membrane. Thus, disruption of the ZO-1 binding site may be the cause of
the trafficking defects seen in the Cx36-EGFP fusion protein and SAYV truncated mutant
(Helbig et al., 2010; Li et al., 2004a).
Although not required for trafficking, phosphorylation has an effect on Cx36
channel function, as protein kinase A (PKA) mediated phosphorylation of Cx36 reduces
intercellular communication (Urschel et al., 2006). Conversely, Kothmann et al (2009)
have shown that dopamine-mediated stimulation of PKA induces dephosphorylation of
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Cx36 through activation of protein phosphatase 2A, resulting in intercellular uncoupling.
Cx36 has also been shown to be phosphorylated by calcium/calmodulin dependent kinase
II (Alev et al., 2008).

1.2.2 Cx36 Channel Properties
Cx36 channels behave differently from those of other connexins, particularly in
response to pH. For example, Cx36 channels close in response to alkalosis, and show
minor increases in coupling during acidosis. Furthermore, the alkalosis gating mechanism
is abolished in certain N and C-terminus mutants, thus demonstrating the role of these
domains in pH gating of Cx36 channels in response to alkalosis (Gonzalez-Nieto et al.,
2008).
Cx36 is unable to pair with other connexins to form heteromeric connexons, nor is
it able to form heterotypic channels with connexins such as Cx32 or Cx26 (Al-Ubaidi et
al., 2000). One study showed that Cx36 is able to form heterotypic channels by docking
with connexons comprised of Cx45 (Al-Ubaidi et al., 2000). However, a more recent
study showed that Cx36 is unable to form heterotypic channels with Cx45, however
homotypic Cx36 and Cx45 channels were recruited to the same plaque (Li et al., 2008).
Although some connexins, including Cx43 and some other connexins such as skate Cx35,
form hemichannels to communicate with the extracellular environment, Cx36 does not
show any hemichannel activity in single Xenopus oocytes (Al-Ubaidi et al., 2000).
However, hemichannel activity has been reported under pathological conditions such as
ischemia (Schock et al., 2008; Orellana et al., 2009).
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1.2.3 Cx36 Expression and Function in Neurons
Cx36 is expressed in neurons, microglia, as well as pancreatic 13 cells (Degen et
al., 2004; Dobrenis et al., 2005; Serre-Beinier et al., 2009). Cx36 is highly expressed in
neurons during development, but is down-regulated in many adult tissues (Belluardo et
al., 2000; Gulisano et al., 2000). In adults Cx36 is expressed in neural tissues such as the
inferior olive, hippocampus, retina, and sympathetic preganglionic motor neurons where
it forms gap junctions on the soma and dendrites of neurons and occasionally on axons
(Connors & Long, 2004; Marina et al., 2008). During development, Cx36 is expressed in
tissues such as the spinal cord, thalamus, and hypothalamus, although it is absent in these
regions or restricted to specific subregions in the adult nervous system. Cx36 is also
highly expressed in the developing rat cerebral cortex, but expression is lost by the
second postnatal week (Belluardo et al., 2000). This downregulation of Cx36 expression
may be due in part to replacement of electrical synapses by chemical synapses, as the
latter begin to form and mature postnatally (Lee et al., 2010).
In neurons, Cx36 is responsible for forming electrical synapses, thereby
regulating neural synchronization and gamma frequency oscillations (Connors & Long,
2004). Gamma frequency oscillations are waves of electrical activity occurring at
approximately 40 Hz, that contribute to attention, learning and memory (Kaiser &
Lutzenberger,

2003).

Cx36

preferentially

couples

inhibitory

intemeurons,

as

demonstrated by studies with a Cx36 knockout mouse model where the Cx36 gene is
replaced with (3 galactosidase and placental alkaline phosphatase reporters (Deans et al.,
2001). In the thalamic reticular nucleus, electrical synapses synchronize action potentials
between adjacent cells, and allow action potentials to propagate to adjacent neurons, even
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in the absence of chemical synapses (Landisman et al., 2002). Interestingly, Cx36 has
been implicated in epileptogenesis, as its expression is increased during the early phases
of epileptic activity. Since seizures arise during bouts of abnormally high and widespread
neural synchronization, Cx36 may contribute to epileptogenesis due to its capacity to
synchronize neurons (Beheshti, 2010).
Therefore, Cx36 is preferentially expressed during development, present in some
adult structures, and has also been linked to pathological conditions of the nervous
system.

1.2.4 Characterization of Cx36 Knockout Mice
Cx36 knockout (KO) mice do not present any obvious physical defects. However,
electrical synapses in the neocortex are largely ablated. Specifically, the synchronization
and power of gamma oscillations of inhibitory neurons, and therefore large-scale
synchronization of inhibitory postsynaptic potentials were diminished (Deans et al., 2001;
Hormuzdi et al., 2001; Buhl et al., 2003). Cx36 KO mice exhibit learning and memory
impairments, in particular for increasingly complex tasks, such as Y-maze and object
memory tasks (Frisch et al, 2005). Similarly, ablation of Cx36-mediated coupling in the
inferior olive disrupts learning-dependent motor timing while not affecting motor
performance (Kistler et al., 2002; Van Der Giessen et al, 2008). Cx36 deficient mice also
experience a disruption in circadian rhythms due to ablation of electrical synapses
between neurons of the suprachiasmatic nucleus (Long et al, 2005). Interestingly, these
mice exhibited increased apoptosis following retinal injury compared to wild type
littermates, introducing a role for Cx36 in cell survival following trauma (Striedinger et
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al., 2005). Thus, although Cx36 is not vital, it is required for successful execution of a
variety of neural tasks ranging from learning and memory to cell survival.

1.3 Connexin 45
1.3.1 Cx45 Expression
Cx45 is found in cardiomyocytes and vascular smooth muscle cells, as well as
other tissues such as bone and skin; however it is also present in neurons (Kumai et al.,
2000; Sohl et al., 2005; von Maltzahn et al., 2009). Cx45 is essential for cardiogenesis, as
Cx45 knockout mice are embryonic lethal due to conduction blocks, and thus heart
failure (Kumai et al., 2000). Cx45 expression is upregulated in several brain regions
during development, including the cortex, hippocampus, and thalamus, and declines
postnatally (Maxeiner et al., 2003; von Maltzahn et al., 2009). Cx45 may also be
involved in neuronal response to apoptosis as it is expressed in apoptotic regions of the
CNS, such as the hippocampus, where it is not normally present in the adult (Condorelli
et al., 2003).

1.4 Gap Junctions and Cancer
1.4.1 Gap Junctions are Perturbed in Cancer
Disturbances in GJIC are implicated in many disease processes, including cancer (Kelsell
et al., 2001). Dysfunctional GJIC may occur between cancer cells, or between cancer
cells and healthy adjacent cells (Mesnil et al., 2005). Numerous studies have shown that
GJIC is decreased or absent in tumor cells due to decreased connexin expression, or
aberrant localization within the cytoplasm rather than at the plasma membrane, thus

12
limiting coupling between cells (Mesnil et al., 2005 Leithe et al., 2006; Czyz, 2008).
Cancer cells exhibit dedifferentiation and proliferation, as indicated by lack of growth
control and specialization (Mesnil et al., 2005). The fact that tumor promoting agents
such as 12-O-tetradecanoylphorbol-13-acetate (TPA) have GJIC inhibiting properties
further illustrates the importance of GJIC in the carcinogenic process (Naus, 2002).
Furthermore, Cx32 knockout mice and Cx43 hemizygous mice are more susceptible to
chemically induced tumorigenesis in the liver (Temme 1997; King & Bertram, 2005).

1.4.2 Connexins as Tumor Suppressors
Overexpression of connexins results in tumor suppression of various cancer types.
For example, Mao et al (2000) have shown that Cx43 has a growth suppressive effect on
the neuroblastoma cell line, Neuro-2A, following overexpression of Cx43 by retroviral
infection. In addition, McLachlan et al (2006) showed that inducing over-expression of
Cx26 and Cx43 suppresses tumor growth and promotes differentiation in breast cancer
cells. Furthermore, connexins display a differential ability to suppress tumor growth,
depending on connexin and tumor type. For example, Cx26 and Cx43 suppress HeLa cell
proliferation, while other connexins do not affect HeLa cell growth (Mesnil, 2002).
Additionally, Cx26 and Cx43 are more potent suppressors of glioma than Cx32 since
they are expressed in healthy astrocytes (Jimenez et al., 2006; Bond et al., 1994). Thus, it
is postulated that connexins preferentially suppress tumors originating from tissues where
the connexin is normally expressed. This differential ability of connexins to act as tumor
suppressors may be due to differences in permeability to transjunctional compounds. For
example, Cx43 overexpressing C6 glioma cells allow glutamate and ATP to pass through
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gap junctions more readily than Cx32 overexpressing cells (Goldberg et al., 2002).
However, connexin-mediated growth suppression is not necessarily due to increased
channel function since connexins have been shown to decrease proliferation without
increases in intercellular communication (Qin et al., 2003; Ionta et al., 2009; Sato et al.,
2007). The role of connexins in growth regulation may also be due to the effects on
connexin binding partners, such as ZO-1. Regarding the specific neuronal gap junction
proteins, there have been no published investigations into the tumor suppressive
properties of Cx36 while Cx45 has decreased expression in transformed nasopharyngeal
tissue and various carcinomas (Xiang et al., 2002; Fan et al., 2003).

1.5 Neuroblastoma
1.5.1 Etiology of Neuroblastoma
Neuroblastoma is an embryonically derived cancer, originating from precursor cells that
deviate from the developmental pathway evading differentiation (Figure 1.3). While
many cancer types originate from terminally differentiated cells that undergo a transition
to an immature phenotype, neuroblastoma involves progenitor cells of the neural crest
(Anderson, 1993a,b). The neural crest (NC) arises during neurulation, when the
notochord induces pinching off of the neural tube from the overlying ectoderm. A variety
of structures arise from the NC, including facial bones, melanocytes, connective tissue,
glia, the dorsal root ganglia, sympathetic neurons, and adrenal chromaffin cells. The NC
is divided into cranial, trunk, sacral, and cardiac components, depending on localization
and the structures they derive. The trunk NC cells migrate to the dorsal aorta, where
environmental

cues,

such

as

bone

morphogenic

protein

4

(BMP4)

induce
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Neural Crest
Neural Tube
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Figure 1.3. Etiology of Neuroblastoma
Neuroblastoma arises from bipotential sympathoadrenal progenitor cells of the neural
crest. Cells of the trunk neural crest migrate to the dorsal aorta, where they are exposed to
environmental cues to form either the sympathetic ganglia or adrenal medulla. These
bipotenial progenitors then migrate to their sites of terminal differentiation. However,
neuroblastoma arises when these progenitors become tumorigenic, and bypass the
differentiation stage to form tumors in the chest, abdomen, and pelvis.
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expression of neuronal markers, such as tyrosine hydroxylase and dopamine (B
hydroxylase (Anderson, 1993b). These cells are known as sympathoadrenal progenitor
cells, and migrate to form the sympathetic ganglia or the adrenal medulla (Huber, 2006).
At the secondary sympathetic ganglia, fibroblast growth factor and nerve growth factor
(NGF) induce the neuronal differentiation of the bipotential progenitors. Conversely,
chromaffin cells downregulate neuronal markers and express chromaffin cell markers in
response to glucocorticoids and BMP4 (Anderson, 1993b). It is along this developmental
pathway, from sympathoadrenal progenitor cells at the dorsal aorta, to sympathetic
neurons at the sympathetic ganglia or chromaffin cells at the adrenal medulla, that
neuroblastoma arises.

1.5.2 Clinical Characteristics of Neuroblastoma
Neuroblastoma is the most common solid, extracranial tumor to present in
pediatric patients, as well as the most common cancer diagnosed in infants. Metastatic
neuroblastoma is present within 60% of diagnosed patients, and is associated with a 5
15% survival rate (Brodeur, 2003). Forty percent of neuroblastoma patients fall within a
high risk category and only 40% of this group are effectively cured with multi-modal
therapy (Wagner & Danks, 2009). Neuroblastoma is characterized by clinical
heterogeneity, with high risk aggressive and metastatic tumors, differentiated tumors that
are relatively benign, and tumors that spontaneously regress to ganglioneuromas.
Interestingly, neuroblastoma has one of the highest rates of spontaneous regression of any
cancer type (Maris, 2010). Poor neuronal differentiation is associated with aggressive
tumors, whereas highly differentiated tumor cells are associated with a more favorable
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prognosis. Tumors usually arise within the adrenal medulla or the paraspinal sympathetic
ganglia in the chest, abdomen, or pelvic ganglia (Brodeur, 2003).
Treatment of high risk neuroblastoma involves multi-modal therapy including
chemotherapy, radiation, and surgery. These treatments are highly toxic to the patient and
are often not well tolerated (Laverdiere et al., 2005). 13-cis retinoic acid is well tolerated
with minimal side effects, and has now been implemented during remission following
standard therapy to eradicate minimal residual disease (Wagner & Danks, 2009).

1.5.3 Markers of Neuroblastoma
There are several prognostic markers for neuroblastoma, such as myc
myelocytomatosis viral related oncogene (MYCN) amplification, and neurotrophin
tyrosine kinase receptor (Trk) A and B expression, which influence the aggressiveness of
the tumor (Brodeur et al, 2009; Schwab, 2004; Bell et al., 2010). TrkA is a receptor for
the neurotrophin, NGF, and its expression is associated with decreased expression of
angiogenic factors (Barbacid, 1995; Brodeur et al., 2009). Since angiogenesis is vital to
tumor progression and metastasis, the down-regulation of angiogenic factors such as
vascular endothelial growth factor is associated with patient survival (Eggert et al., 2002).
Conversely, TrkB is a receptor for brain derived neurotrophic factor (BDNF) and
associated with increased proliferation and poor prognosis (Barbacid, 1995; Schramm et
al, 2005).

1.5.3.1 MYCN
MYCN is amplified in 20% of all neuroblastomas. MYCN belongs to the MYC
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family of transcription factors. MYCN heterodimerizes with MAX and binds to E-box
sequences to activate transcription. MYCN can also repress transcription by recruiting
DNA methyltransferases to target genes (Bell et al., 2010). MYCN is an oncogene, and its
overexpression results in increased proliferation by regulation of genes involved in cell
cycle progression. Specifically, activation of the MYCN signaling pathway is strongly
correlated with poor prognosis (Bordow et al., 1998; Fredlund et al., 2008). Transgenic
mice overexpressing mycn under a tyrosine hydroxylase promoter, which targets cells of
neuroectodermal lineage, spontaneously develop neuroblastoma within months after birth
(Weiss et al, 1995).

1.6 Differentiation Therapy
1.6.1 Differentiation Therapy
Neoplastic cells acquire an immature phenotype characteristic of undifferentiated
cells, displaying increased proliferation and invasiveness. Differentiation therapy is based
on the concept that exposing cancer cells to differentiating agents will cause arrest of
proliferation and promote differentiation, which sensitizes cells to cancer drugs. For
example, SH-SY5Y human neuroblastoma cells are more prone to undergo apoptosis in
response to flavonoids when they are pretreated with the differentiating agent, retinoic
acid (Das et al., 2009). The efficacy of differentiation therapy has been established in
multiple cancers such as melanoma, acute promyelocytic leukemia (APL), and
neuroblastoma. 13-cis retinoic acid has been clinically employed in differentiation
therapy of aggressive neuroblastoma following chemotherapy (Reynolds 2003). Alltrans-retinoic acid (ATRA) has been used to effectively treat APL (Leszczyniecka, 2001).
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13-cis retinoic acid is now implemented in standard therapy during the first remission of
high risk neuroblastoma patients. Furthermore, the efficacy of other derivatives of
retinoic acid, including the synthetic retinoic, N-(4-hydroxyphenyl) retinamide (4-HPR or
fenretinide), is currently being investigated. (Maris, 2010; Wagner & Danks, 2009).
Specifically, 4-HPR is now being tested in Phase I clinical trials and shows promise due
to minimal toxic effects and tolerance by patients (Wagner & Danks, 2009).

1.6.2 Retinoic Acid
Retinoic Acid (RA) is a derivative of Vitamin A. It exists in many isomers,
including ATRA, 13-cis retinoic acid, and a synthetic derivative, 4-HPR (Reynolds
2003). Retinoic acid acts by binding to retinoic acid receptors (RAR) or retinoid X
receptors (RXR), which are members of the steroid/thyroid hormone family of
transcription factors (Glass et al., 1991). Specifically RAR binds ATRA and 13-cis
retinoic acid, whereas RXR only binds 13-cis RA. RAR and RXR are bound to nuclear
corepressors until retinoic acid binds the receptors and causes a conformational change to
release the corepressors (Linney, 1992). RAR and RXR then bind retinoic acid response
elements in the promoter regions of target genes, and activate transcription (Reynolds
2001). Retinoic acid is endogenously synthesized during development and in adults. Lack
of Vitamin A or RA during development is lethal. In vitro, ATRA diminishes MYCN
expression, arrests proliferation, and induces differentiation of neuroblastoma cells
(Thiele et al., 1985). The mechanism of ATRA mediated differentiation may be through
TrkA and TrkB activation, sensitizing them to NGF and BDNF respectively (ClagettDame et al., 2006). Conversely, 4-HPR induces cell death of neuroblastoma cells,
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including cells that are resistant to 13-cis retinoic acid and ATRA (Reynolds et al., 2003).
In relation to gap junctions, RA increases GJIC and Cx43 expression (Bertram & Vine,
2005; Stahl & Sies, 1998; Long et al., 2010; King & Bertram, 2005). Interestingly, the
mouse Cx36 gene contains an RXR binding motif and a MYCN binding site, indicating
that Cx36 is susceptible to transcriptional regulation by RA and MYCN (Cicirata et al.,
2000). No studies have explored the effects of retinoic acid on Cx36 or Cx45 in
neuroblastoma or any other cancer cell lines thus far.

1.6.3 Neuritogenesis
Neurites are cytoplasmic extensions of the neuron cell body, forming the
precursors of axons and dendrites. The growth cone is the mobile and dynamic front of
the neurite. (Clagett-Dame et al., 2006). It guides the neurite to other neurons or
nutrients. Neuritogenesis is a dynamic process involving reorganization of the
cytoskeleton, specifically of actin and microtubules. Actin filaments comprise the
peripheral domain of the growth cone, where they organize in a loose meshwork to form
lamellopodia, and tight bundles to form filopodia (Bouqet & Nothias, 2007; ClagettDame et al., 2006). The central domain is filled with microtubules that stabilize the
neurite (Bouqet & Nothias, 2007). Neuritogenesis is a function of neuronal differentiation
and thus is often used as a measure to quantify the extent of differentiation (Belliveau et
al., 1997; Belliveau et al., 2006; Encinas et al., 2000; Pahlman et al., 1990).

1.6.3.1 Gap43
Growth associated protein 43 (Gap43) is found at very high concentrations in the
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1.7 Rationale, Hypothesis and Aims
1.7.1 Rationale
Gap junctional intercellular communication is often disrupted in cancer cells.
Many connexins have been shown to be downregulated in neoplasms, and the
overexpression of these connexins results in tumor suppression. Connexin family
members also enhance differentiation in cells of the neuroectodermal lineage. In addition,
Cx43 is shown to be responsive to retinoic acid signaling and Cx36 has an identical
binding site for RXR; however the effect of retinoic acid on Cx36 has not yet been
investigated. Although Cx36 expression patterns have been extensively investigated, the
expression and role of Cx36 in cancer cells have not been assessed. Since Cx36 is
predominantly a neuronal connexin, and the ability of connexins to act as tumor
suppressors is specific to tissues in which they are normally expressed, the effect of Cx36
on the neuronal tumor, neuroblastoma, was investigated. In this study, I explored the
effects of the differentiating agent, all-trans-retinoic acid, on Cx36 expression in the SHSY5Y, human neuroblastoma cell line. The SH-SY5Y cell line has been utilized as a
model system for neural diseases, as well as in many studies of differentiation.
Furthermore, I investigated the role of Cx36 on tumor cell characteristics by
manipulating Cx36 expression and assessing proliferation and features of differentiation,
such as neuritogenesis and differentiation marker expression of human neuroblastoma
cells. My study is the first to explore the role of Cx36 in the tumor cell phenotype.
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1.7.2 Hypothesis
Cx36 regulates the differentiation and proliferation of human neuroblastoma cells.

1.7.3 Aims
1. Determine the changes in connexin gene expression following retinoic
acid induced differentiation of neuroblastoma.
2. Investigate the effects of Cx36 overexpression on differentiation and
proliferation of human neuroblastoma cells,
3. Investigate the effects of knocking down Cx36 on differentiation and
proliferation of human neuroblastoma cells.
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2.1 Introduction
Neuroblastoma is the most common extracranial solid tumor to present in children
(Brodeur, 2003). Forty percent of neuroblastoma patients fall within a high risk category,
and only 40% of this group are effectively cured with multi-modal therapy (Wagner &
Danks, 2009). Neuroblastoma arises from bipotential sympathoadrenal progenitor cells of
the trunk neural crest. In normal development, sympathoadrenal progenitors differentiate
to form the sympathetic ganglia and adrenal medulla, however in neuroblastoma they
form tumors at these sites instead (Anderson, 1993; Huber, 2006; Brodeur, 1994).
Retinoic acid is used as an adjunct to multi-modal therapy to treat high-risk
neuroblastoma and eradicate minimal residual disease (Reynolds, 2003; Wagner &
Danks, 2009). Retinoic acid is a Vitamin A derivative that induces differentiation in
several cell types (Das et al., 2009; Reynolds, 2003; Reynolds, 2001; Melino et al.,
1997). For example, all trans retinoic acid (ATRA) diminishes MYCN oncogene
expression, arrests proliferation, and induces differentiation of neuroblastoma cells
(Thiele et al., 1985; Sidell et al., 1983).
Gap junctional intercellular communication (GJIC) and connexins (Cx) have been
implicated in carcinogenesis and differentiation. GJIC is often perturbed and connexins
are typically downregulated or aberrantly localized in cancer cells (Ozawa et al., 2007;
Arnold et al., 2005; Naus, 2002; Czyz, 2008; Li et al., 2007). Many connexins have been
identified as tumor suppressors when overexpressed in cancer cells (Jimenez et al., 2006;
Zhang et al., 1998; Temme et al., 1997; Sato et al., 2007; McLachlan et al., 2006). For
example, overexpression of Cx43 resulted in growth suppression of communication
deficient Neuro-2A murine neuroblastoma cells (Mao et al., 2000). In addition, connexins
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have been shown to enhance differentiation in several cancer cell lines (Vinken et al.,
2006; Banks et al., 2007; Brehm et al., 2007; Mao et al., 2000). For example,
overexpression of Cx32 and Cx43 resulted in enhanced nerve growth factor induced
neurite outgrowth in PC 12 cells (Belliveau et al., 2006).
Gap junctions are membrane channels that allow intercellular communication
between adjacent cells (Laird, 1996). GJIC involves the passage of ions, second
messengers, and metabolites less than lkDa in size between cells (Goldberg et al., 1998;
Goldberg et al., 1999; Saez et al., 1989). Gap junctions and their constituent proteins,
connexins, regulate cellular processes such as homeostasis, growth, and differentiation
(Vinken et al., 2006; Churko et al., 2010; Prost et al., 2008; Ionta et al., 2009; Omori et
al., 2001). Gap junctions are formed from the docking of two connexons or hemichannels
contributed by adjacent cells. Each connexon in turn is comprised of a hexamer of
connexin subunits (Laird, 1996). There are 21 known members of the human connexin
family, most with unique spatial and temporal expression patterns (Ahn et al., 2008;
Belluardo et al., 2000; Boucher & Bennett, 2003; Cina et al., 2007; Kihara et al., 2006).
Cx36 is a recently identified connexin that is expressed in neurons and pancreatic
beta cells (Sohl et al., 1998; Condorelli et al., 1998; Serre-Beinier et al., 2000;
Wellerhaus et al., 2008). Cx36 is highly expressed in the developing nervous system,
however its expression is decreased or lost by the second post-natal week in many
structures (Belluardo et al., 2000; Gulisano et al., 2000). In adults, Cx36 is the
predominant connexin involved in electrical synapses (Connors & Long, 2004). It is
primarily responsible for large-scale synchronization of gamma frequency oscillations in
inhibitory interneurons (Deans et al., 2001).
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The differentiating agent, retinoic acid, increases gap junctional intercellular
communication and Cx43 expression in multiple cell types (Bertram & Vine, 2005; Stahl
& Sies, 1998; Long et al., 2010). Interestingly, the mouse Cx36 gene contains a retinoid
X receptor binding motif indicating that Cx36 may be susceptible to transcriptional
regulation by retinoic acid (Cicirata et al., 2000).
In this study, I explored the effect of the neuronal connexin, Cx36, on the
differentiation of SH-SY5Y human neuroblastoma cells. SH-SY5Y cells are often
utilized as a model system for studies of neural disease, as well as in studies of
differentiation (Encinas et al., 2002; Agholme et al., 2010; Cheung et al., 2009). The
effect all-trans-retinoic acid on Cx36 expression was first examined in SH-SY5Y cells.
Furthermore, the effects of Cx36 on proliferation and features of differentiation including
neuritogenesis and molecular differentiation marker expression were investigated by
manipulating Cx36 expression.
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2.2 Methods
2.2.1 Cell Culture
The neuroblastoma cell line, SH-SY5Y was obtained from American Type Culture
Collection (Manassas, VA). SH-SY5Y is a proliferative cell line with a documented
doubling time of 48 hours. SH-SY5Y cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM, Invitrogen) with high glucose, and supplemented with 10% fetal
bovine serum (FBS, HyClone), 100 U/ml penicillin and streptomycin (Invitrogen) and 2
mM L-glutamine (Invitrogen). For cell passage, cells were washed with Hank’s Buffered
Salt Solution (HBSS, Sigma), treated with 0.25% trypsin and incubated for 5 minutes at
37°C to disperse the cells. Five ml of growth medium was added to the cells, and they
were resuspended in a 10 cm dish in fresh growth medium after pipetting several times.

2.2.2 Generation of Stable Cell Lines
2.2.2.1 Overexpression
Cells were plated at a density of lxlO6 cells per well in a 6-well dish. The following
day, 4 pg of Cx36myc-DDK (Origene, Rockville, MD) or EGFP pcDNA3.1 were diluted
in OPTI-MEM (Invitrogen) and mixed with 2.5 pi of lipofectamine 2000 (Invitrogen) in
OPTI-MEM. The DNA and lipofectamine were mixed and the resulting complexes added
to the cells after 20 minutes, which were also in OPTI-MEM. The cells and complexes
were incubated for 6 hours and then returned to normal growth medium. The following
day, transfected cells were passaged onto 10 cm dishes. Kill curves were performed on
wild-type cells to determine optimal antibiotic concentrations. For stable cell lines, 800
pg/ml G418 was added to the cells, and all viable cells were passaged to a 10 cm dish
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following two weeks of selection, and G418 was reduced to 200 pg/ml. However, cells
were treated with 800 gg/ml G 418 monthly to ensure purity of the culture.

2.2.2.2 Knockdown
shRNA knockdown: Cells were plated at a density of SxlO5 cells per well in a 6well dish. The following day, 1 pg of four distinct shRNAs targeting Cx36 or non
effective (scrambled) control plasmids co-expressing GFP (Origene, Rockville, MD)
were diluted in OPTI-MEM and mixed with 1.5 pi of lipofectamine 2000 in OPTI-MEM.
The cells were then maintained as per the overexpression protocol. For stable cell lines,
800 ng/ml puromycin was added to the cells, and all viable cells were passaged to a 10
cm dish following two weeks of selection, and puromycin was further increased to 1.5
pg/ml. In addition, cells were treated with 2.5 pg/ml puromycin monthly to maintain
purity of the culture due to the occasional appearance of non-fluorescent cells.

2.2.3 Differentiation Assay
SHSY-5Y cells were plated on rat-tail collagen coated 6-well or 60 mm plates, at a
density of 10 000 cells/cm2 in growth medium. The following day, cells were treated with
10 pM of all trans-retinoic acid (Sigma) for 4 days, with medium and treatment refreshed
every 2 days. Cells were then washed with HBSS and treated with 20 ng/ml of brain
derived neurotrophic factor (BDNF) in serum-free DMEM for 6 days, with medium and
BDNF replaced every 2 days (modified from Encinas et al., 2000). Medium for
transfected cells contained the appropriate antibiotic. RNA and protein were extracted at
Days 0, 2, 4 and 10 of differentiation, and connexin and differentiation marker expression
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were analyzed. Images were taken at each timepoint with a Leica inverted epifluorescent
microscope. The images were analyzed with the NeuronJ plugin for ImageJ (E. Meijering
et al., 2004; Abramoff et al., 2004). For each image, neurites within the 0.16 mm2 field of
view were traced. Neurites were classified as cell projections longer than one cell body
length. For analysis of average neurite length, the mean length of all neurites in the field
of view was computed. In order to calculate maximum neurite length, the length of the
longest neurite in the field of view was analyzed. Finally, for neurite density, the number
of neurites was divided by the number of cell bodies in the field of view.

2.2.4 Real-Time PCR
RNA was extracted and purified using the Qiagen RNeasy mini kit, and 0.5 pg of
RNA was reverse transcribed using the qScript cDNA synthesis kit (Quanta Biosciences).
Connexin primers were designed using Primer-Blast yielding the following sense and
anti-sense sequences: Cx36, 5’-AAG GCA TCT CCC GCT TCT ACA - 3’ and 5’- GCC
AAC CAG GAA CCC AAT TT- 3’; Cx45, 5’-CTG GAG GCT CTG CAG CGG GA- 3’
and 5’-TCT CCC GGG GAC CAT GAG GG- 3’; Cx43, 5’-GGT TAC ACT TGC AAA
AGA GAT C- 3’, and 5’-GAG CAG CCA TTG AAA TAA GC- 3’. Differentiation
markers: Neuropeptide Y (NPY), 5’- TCC AGC CCA GAG ACA CTG ATT-3’ and 5’AGG GTC TTC A AG CCG AGT TCT-3’; Growth associated protein 43 (Gap43), 5’ACG ACC AAA AGA TTG AAC AAG ATG-3’ and 5’-TCC ACG GAA GCT AGC
CTG AA-3’ (Origene). Adhesion molecule: Neural cell adhesion molecule (NCAM), 5’CAT CAC CTG GAG GAC TTC TAC C-3’ and 5’- CAG TGT ACT GGA TGC TCT
TCA GG- 3’ (Origene). Values were normalized to those of the PPIA reference gene:
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cyclophillin A (PPIA), 5’-AGA CAA GGT CCC AAA GAC-3’ and 5’ACC ACC CTG
ACA CAT AAA-3’. All primer pairs were tested using standard curves with 10-fold
serial dilutions, and selected only if the effiencies were within the 95-110% range over a
minimum of 3 points. Three technical repeats were included for each biological replicate.
The qPCR was performed in the CFX96 Real-Time PCR Detection System (Bio-Rad)
using Perfecta Sybr Green Fastmix (Quanta Biosciences), and the data analyzed with
CFX Manager software (Bio-Rad).

2.2.5 Western Blot Analysis
Protein was extracted using 18 mM Tris, 123mM NaCl, 10% glycerol, 1% NP40,
and protease inhibitor cocktail (Calbiochem). Cell lysates were kept on ice for 5 minutes
with frequent agitation, sonicated for 10 seconds, and lysates were cleared in a cold
centrifuge at 10,000 rpm for 10 minutes. The supernatant was removed and used for
western blotting. Protein concentration was measured using the BCA Protein Assay
(Thermo Scientific, Rockford, IL). Thirty pg of protein were electrophoresed on 10%
polyacrylamide gels and transferred to a nitrocellulose membrane. The membrane was
blocked for one hour in 3% bovine serum albumin (BSA) in phosphate buffered saline
with 0.05% Tween-20 (PBST), followed by incubation with primary antibodies: mouse
monoclonal Gap43 (Invitrogen) 1:500 overnight at 4°C; mouse monoclonal N-cadherin
(BD) 1:2500 2 hours at room temperature; mouse monoclonal GAPDF1 (Millipore)
1:5000 for 2 hours at room temperature. Membranes were washed with PBST and
incubated with secondary antibodies for one hour: horseradish peroxidase conjugated
goat anti-mouse at a 1:5000 dilution (Thermo Scientific, Rockford, IL). Membranes were
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then washed with PBST and developed using enhanced chemiluminscence (Thermo
Scientific, Rockford, IL). Protein expression data could not be collected for Cx36 due to
unreliable antibodies.
Protein expression was quantified with Quantity One software (Bio-Rad) by
densitométrie analysis. Protein levels were normalized to GAPDH.

2.2.6 MTT Proliferation Assay
Cells were plated at 20, 000 cells per well in a 48-well plate. At 0, 2, 4, and 6 days,
20 pi of MTT (Invitrogen) solution was added to each well and incubated for 4 hours.
200 pi of SDS-HC1 was then added to each well and incubated for 14 hours. The
absorbance was measured at 570 nm on a pQuant Biomolecular spectrophotometer (Bio
Tek). Increased absorbance indicates higher cell numbers. Four technical repeats were
included in each biological replicate.

2.2.7 Statistical Analysis
Student’s t-test was conducted for aggregate and neuritogenesis analysis between
EGFP and Cx36 overexpressing cells. One-way analysis of variance (ANOVA) was
conducted for the following experiments: gene expression analysis between wild-type
cells, and neuritogenesis analysis between non-effective shRNA and Cx36 shRNAs.
Tukey’s multiple comparison post-hoc test was used to assess differences in means
between groups.
Two-way ANOVA was conducted for the following experiments: All gene and
protein expression analysis and proliferation assays between transfected cells
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(overexpression and knockdown). Bonferroni’s post-hoc test was conducted to assess
differences in means between groups. p<0.05 was considered significant for all tests. All
statistical analysis was performed with GraphPad Prism 4.0 software.
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2.3 Results
2.3.1 Retinoic Acid Induces Differentiation and Upregulates Cx36 Expression of SHSY5Y Neuroblastoma Cells
SH-SY5Y cells were exposed to retinoic acid and BDNF treatment to induce cell
differentiation. SH-SY5Y cells were treated with 10 pM retinoic acid in growth medium
for 4 days, followed by 20 ng/ml BDNF for 6 days to induce differentiation. Neurite
outgrowth was observed in treated cells beginning at day 2 (Figure 2.1C). Neuritogenesis
continued through day 4, and within 10 days extensive neurite networking was observed
(Figure 2.1 E & G). Untreated cells began to cluster and form aggregates by day 2, and
continued to form large aggregates by day 10 (Figure 2.1 B, D, F). Thus, retinoic acid
and BDNF treatment induces the morphological differentiation of SH-SY5Y cells.
In order to determine whether retinoic acid regulates the expression of neuronal
connexins, the effect of retinoic acid treatment on Cx36 and Cx45 transcript expression
was examined. Gap43 transcript expression was also assessed to confirm differentiation
at the molecular level. RNA was isolated from untreated and treated cells at 0, 2, 4 and 10
days. Real-time PCR was used to quantify gene expression. Cx36 mRNA was increased
in treated cells at 2 (2.6-fold), 4 (1.8-fold), and 10 (13.9-fold) days compared to untreated
cells (Figure 2.2A). Cx45 mRNA, however, did not increase in treated cells (Figure
2.2B). Messenger RNA for the growth cone marker, Gap43, was upregulated at days 4
(2-fold) and 10 (2.8-fold) of treatment compared to untreated cells (Figure 2.2C). The
drop in Gap43 expression following day 0 appears to be an artifact, possibly due to its
initial mRNA upregulation following cell seeding. It does not appear in western blots in

Figure 2.1. Retinoic acid induces neuritogenesis in SH-SY5Y cells.
Cells were seeded on rat-tail collagen coated dishes (A) and treated with 10 nM of
retinoic acid the following day. During days 5-10, cells were treated with 20
ng/ml of BDNF in serum-free medium. Untreated cells formed increasingly larger
aggregates over time (B, D, F). Neurite outgrowth (arrows) was observed
beginning at days 2 and 4 of treatment (C, E), and dense neurite networks were
formed following 10 days of treatment (G). Scale bar = 100 (Jm.

Day 10

Day 4

Day 2
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Figure 2.2. C x36 and G ap43 are transcriptionally upregulated following retinoic
acid induced differentiation of SH-SY5Y cells.
RNA was isolated from SH-SY5Y cells at days 0, 2, 4, and 10 of treatment. Real
time PCR was used to quantify mRNA expression. Cx36 expression increased
following 2, 4 and 10 days of treatment, as compared to untreated cells (A). Cx45
expression did not increase in either treated or untreated cells (B). Gap43
expression increased following 4 and 10 days of treatment (C). mRNA levels
were normalized to PPIA. N=3 (DaylO, N=5). Asterisks denote statistical
significance. p<0.05. Bars show mean +/- S.E.
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overexpression and knockdown experiments. These results indicate that transcription of
the gene encoding Cx36 is upregulated by retinoic acid signaling while Cx45 mRNA
expression is unaffected.

2.3.2 Cx36 Suppresses Neuritogenesis
Cx36 mRNA was either overexpressed or knocked down in SH-SY5Y cells to
determine the effect of Cx36 on differentiation. SH-SY5Y cells were transfected and
selected to stably overexpress Cx36 mRNA. Cx36 overexpressing cells expressed
approximately 150 fold (141 +/- 27) more Cx36 mRNA than EGFP transfected cells
(Figure 2.3A). Cx36 overexpression was maintained over the ten-day differentiation
treatment (Figure A .l). Prior to beginning experiments, Cx36 shRNA expressing cells
exhibited an 88-99% reduction in Cx36 mRNA levels in comparison to non-effective
shRNA control (Figure 2.3B). Unfortunately, real-time PCR provided inconsistent results
in knockdown detection. Since all shRNA constructs coexpress GFP, fluorescence was
visualized to ensure continued expression of the construct during differentiation. The
majority of differentiating cells (>85%) continued to express all constructs during the ten
day experiments, although the cell population was not entirely homogenous for GFP
expression (Figure 2.4). Therefore, all constructs were successfully transfected and
expressed by SH-SY5Y cells.
Cx36 overexpressing cells were induced to differentiate in order to determine the
effect of Cx36 on neuritogenesis. EGFP and Cx36 overexpressing cells were seeded for

Figure 2.3. Stable transfection of SH-SY5Y cells with a construct encoding Cx36
results in C x36 mRNA overexpression and transfection with shRNA results in C x36
mRNA knockdown.
SH-SY5Y cells were transfected and selected to stably overexpress Cx36
or EGFP as a transfection control. In addition, cells were transfected and selected
to express four distinct Cx36 shRNA’s and a non-effective shRNA transfection
control. RNA was isolated to determine expression levels prior to seeding cells
for experiments. Cx36 overexpressing cells expressed increased transcript levels
of Cx36 compared to EGFP control (A). Cx36 shRNA expressing cells had
decreased Cx36 transcript levels (B). RNA expression levels were normalized to
PPIA mRNA. N=3 (B, N=l). Asterisk denotes statistical significance compared
to EGFP. p<0.05. Bars show mean +/-S.E.
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SH-SY5Y cells were stably transfected to express Cx36 shRNA or non
effective shRNA control constructs that coexpress GFP. Most of the cell
population expressed GFP through ten days of differentiation treatment (A l, Bl,
C l), however some non-fluorescent cells were present within the culture (A2, B2,
C3). Scale bar = 100 pm.
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differentiation, and imaged at 0, 2, 4, and 10 days following differentiation treatment.
EGFP expressing cells showed intense neurite networking by day 10 of differentiation
treatment (Figure 2.5 C, E, G), while Cx36 overexpression diminished neuritogenesis
(Figure 2.5 J, L M). There was no significant difference between EGFP and Cx36
overexpressing cells in average or maximum neurite length (Figure 2.6 A, B). However,
Cx36 overexpressing cells had significantly reduced neurite density (1.0 neurite per cell
body) compared to EGFP expressing cells (1.5 neurites per cell body) (Figure 2.6C).
Thus, my findings indicate that Cx36 downregulates retinoic acid induced neuritogenesis.
In order to verify that Cx36 negatively regulates neuritogenesis, the effect of
Cx36 knockdown on neuritogenesis was determined. An identical experimental design as
the overexpression study was conducted between non-effective shRNA and Cx36 shRNA
expressing cells. In these experiments, Cx36 shRNA expressing cells showed enhanced
neuritogenesis (Figure 2.7 H, J). There was no significant difference in average neurite
length between Cx36 shRNA expressing and non-effective shRNA expressing cells
(Figure 2.8A). However, maximum neurite length was significantly increased in Cx36
shRNA expressing cells (shRNA 1: 217 pm; shRNA 4: 263 pm) over non-effective
shRNA expressing cells (163 pm) (Figure 2.8B). Neurite density was also significantly
increased in Cx36 shRNA expressing cells (shRNA 1: 1.8 neurites per cell body; shRNA
4: 1.5 neurites per cell body) compared to non-effective shRNA expressing cells (0.9
neurites per cell body) (Figure 2.8C). Therefore, knockdown of Cx36 enhanced retinoic
acid induced neuritogenesis. These findings confirm that Cx36 downregulates retinoic
acid induced neuritogenesis of SH-SY5Y cells.

Figure

2.5.

Cx36

overexpression

increases

cell

clumping

and

diminishes

neuritogenesis in SH-SY5Y cells.
Stably transfected EGFP and Cx36 overexpressing SH-SY5Y cells were treated
with retinoic acid and BDNF. Untreated Cx36 overexpressing cells formed
numerous small cell clumps (I, K, M) whereas EGFP expressing cells formed
larger aggregates (B, D, F). EGFP expressing cells (C, E, G) formed denser
neurite networks than Cx36 overexpressing cells following treatment (J, L, M).
Arrows identify neurites. Scale Bar = 100 pm. Insert scale bar= 50 pm.
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Figure 2.6. Overexpression of Cx36 diminishes neurite density in differentiating SHSY5Y cells.
Cells were seeded and subjected to 10 days of differentiation treatment. Cells
were imaged and neurite length and density were measured using Neuron J. There
was no significant difference in average (A) and maximum neurite length (B)
between EGFP control and Cx36 overexpressing cells. However, neurite density
was lower in Cx36 overexpressing cells than in EGFP control cells. N=3. Asterisk
denotes statistical significance compared to EGFP. p<0.05. Bars show mean +/S.E.
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Figure 2.7. Cx36 knockdown suppresses aggregate formation and enhances
neuritogenesis in SH-SY5Y cells.
Cells were plated and subjected to differentiation treatment over 10 days.
Untreated non-effective shRNA expressing cells aggregate on collagen (B, D),
while Cx36 shRNA expressing cells remain dispersed (G, I). At Day 10, more
neurites (white arrows) were observed in the differentiating Cx36 shRNA
expressing cells (J) than in non-effective shRNA control cells (E). Scale bar = 100
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2.3.3 Cx36 Suppresses Differentiation Marker Expression
In order to determine whether Cx36 also negatively regulates other indicators of
differentiation, the effect of Cx36 on the expression of molecular differentiation markers,
Gap43 and NPY, was assessed. Transcript expression of the Gap43 differentiation
marker was significantly reduced in Cx36 overexpressing cells at days 2 (18-fold
decrease) and 4 (11.7-fold decrease) of treatment in comparison with EGFP expressing
cells (Figure 2.9A). Gap43 protein expression significantly increased upon differentiation
treatment in EGFP expressing cells, however Cx36 overexpressing cells failed to increase
Gap43 expression following treatment (Figure 2.9 B & C). NPY mRNA levels were also
significantly decreased in Cx36 overexpressing cells at days 2 and 10 of treatment (Day
2: 24-fold; Day 10: 7.2-fold reduction) compared to EGFP expressing cells (Figure
2.9D). Thus, Cx36 overexpression diminished retinoic acid induced expression of
molecular differentiation markers.
The impact of Cx36 knockdown on expression of differentiation markers was
assessed to confirm the effect of Cx36 on differentiation. Non-effective shRNA and Cx36
shRNA expressing cells were subjected to 10 days of differentiation treatment, and RNA
was isolated at days 0, 4, and 10. Cx36 shRNA expressing cells had significantly
increased levels of Gap43 mRNA expression at day 10 of treatment (shRNAl: 6.9-fold;
shRNA 4: 1.6-fold) compared with non-effective shRNA expressing cells (Figure 2.10A).
Untreated and treated Cx36 knockdown cells also expressed higher levels of Gap43
protein (Figure 2.10 B & C). Furthermore, untreated Cx36 shRNA expressing cells
expressed as much Gap43 mRNA and protein as treated non-effective control, while
treated Cx36 shRNA expressing cells expressed the highest levels of Gap43. In addition,

Figure 2.9. Cx36 overexpression diminishes retinoic acid induced Gap43 and N P Y
expression.
RNA was isolated from cells at day 0, 2, 4, and 10 of differentiation treatment,
and real-time PCR was used to quantify changes in mRNA expression. Protein
was extracted from cells at 0 and 10 days of treatment and western blot analysis
was used to quantify protein expression. Gap43 expression was diminished in
Cx36 overexpressing cells at days 2 and 4 of treatment (A). Gap43 protein
expression did not significantly differ between Cx36 overexpressing and EGFP
expressing cells. Gap43 expression significantly increased upon treatment in
EGFP cells, however it failed to increase in treated Cx36 overexpressing cells (B
& C). NPY expression is diminished at days 2 and 10 of treatment in Cx36
overexpressing cells (D). mRNA levels were normalized to PPIA and protein
levels to GAPDH. N=3. Asterisks indicate statistical significance. Bars
represented by different letters denote a statistically significant difference. p<0.05.
Bars show mean +/- S.E.
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Cx36 shRNA expressing cells had significantly higher NPY mRNA expression at day 0
(1.6-fold) and day 10 (shRNA 1: 6-fold; shRNA 4: 3.6-fold) of differentiation treatment
compared to non-effective shRNA expressing cells (Figure 2.10D). My findings show
that Cx36 knockdown enhances retinoic acid induced differentiation marker expression.

2.3.4 Cx36 Promotes Cell Clumping
An unexpected finding was that Cx36 overexpression affected the adhesion and
aggregation properties of cells on collagen coated dishes. EGFP and Cx36 overexpressing
cells were plated on collagen coated plates for ten days. EGFP expressing cells behaved
like wild-type cells, where they formed large cell aggregates over time (Figure 2.5 B, D,
F). Cx36 overexpressing cells formed cell clumps that were susceptible to lifting off the
plate (Figure 2.5 I, K, M). Cx36 overexpressing cells formed significantly smaller
aggregates than EGFP expressing cells (Figure 2.11 A) in addition to significantly higher
numbers of cell clumps (3.7 aggregates per field of view) than EGFP expressing cells
(1.3 clumps per field of view) (Figure 2.1 IB). NCAM and N-cadherin expression levels
were examined to determine whether altered expression of these adhesion proteins was
mediating the cell clumping in Cx36 overexpressing cells. However, neither NCAM
mRNA nor N-cadherin protein levels showed any significant changes in Cx36
overexpressing cells during differentiation or in their untreated state (Figure A.2).
Therefore, Cx36 overexpression resulted in increased formation of small cell clumps,
although the adhesion molecules involved in this process have not yet been identified.

Figure 2.11. Cx36 overexpression increases the number of small cell clumps.
EGFP and Cx36 overexpressing SH-SY5Y cells were plated on collagen coated
dishes. Following 10 days in culture, images were taken and aggregate area and
number were measured. Cx36 overexpressing cells formed aggregates with
significantly smaller area (A), however developed more numerous aggregates per
field of view (B) than EGFP expressing cells. N=3. Asterisks indicate statistical
significance compared to EGFP. p<0.05. Bars show mean +/- S.E.
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In order to confirm the effect of Cx36 on cell clumping, the effect of Cx36
knockdown on aggregate formation was assessed in a comparable study between non
effective shRNA and Cx36 shRNA expressing SH-SY5Y cells. The non-effective shRNA
expressing cells formed large aggregates over ten days, similar to wild-type cells (Figure
2.7 B & D). However, Cx36 shRNA expressing cells did not form aggregates, and
maintained a dispersed phenotype (Figure 2.7 G & I). NCAM expression was
significantly higher in treated non-effective shRNA expressing cells than all other
conditions (Figure A.3A). N-cadherin expression was reduced in Cx36 shRNA4
expressing cells, however, Cx36 shRNA 1 expressing cells showed no difference in Ncadherin expression from non-effective control (Figure A.3 B & C). Therefore, Cx36
knockdown prevents aggregate and cell clump formation in SH-SY5Y cells. However,
the molecules through which Cx36 exerts its effect on cell aggregation have not yet been
determined.

2.3.5 Cx36 Increases SH-SY5Y Cell Proliferation
Neurons typically exit the cell cycle in order to terminally differentiate. Thus, cell
proliferation was assessed in Cx36 overexpressing and knockdown cells to determine if
changes in proliferation rate are a consequence of Cx36 manipulation of differentiation.
EGFP and Cx36 overexpressing cells were seeded in 48-well plates and assessed using
the MTT proliferation assay. Absorbance was measured at 0, 2, 4, and 6 days in culture.
At day 6, Cx36 overexpressing cells had significantly higher absorbance than EGFP
expressing cells implying enhanced cell proliferation in these cells (Figure 2.12).
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Figure 2.12. Cx36 overexpression increases SH-SY5Y cell proliferation.
Cells were seeded at 20,000 cells per well in 48-well plates and the MTT
proliferation assay was conducted according to manufacturer’s guidelines.
Following 6 days in culture, Cx36 overexpressing cells had a significantly higher
proliferation rate than EGFP control cells. Different letters indicate significant
difference. p< 0.05. N=3. Points show mean +/-S.E.
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The identical assay was performed for non-effective shRNA and Cx36 shRNA
expressing cells to confirm that Cx36 stimulates cell proliferation. At day 6, Cx36
shRNA expressing cells had significantly reduced absorbance in comparison to non
effective shRNA expressing cells (Figure 2.13). Therefore, my findings indicate that
Cx36 promotes proliferation of SH-SY5Y neuroblastoma cells.
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Figure 2.13. Cx36 knockdown decreases proliferation of SH-SY5Y cells.
Cells were seeded at 20,000 cells per well in 48-well plates and the MTT
proliferation assay was conducted according to manufacturer’s guidelines.
Following 6 days in culture, Cx36 shRNA expressing cells had a significantly
lower rate of proliferation than non-effective shRNA expressing control cells.
Different letters indicate significant difference. p<0.05. N=3. Points show mean
+/-S.E.
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2.4 Discussion
2.4.1 Retinoic Acid Induces Upregulation of Cx36
Retinoic acid is often used as a therapeutic agent in the treatment of
neuroblastoma to induce differentiation. In current neuroblastoma treatment, patients are
given 13-cis retinoic acid during remission following treatment with chemotherapeutics
to eradicate minimal residual disease (Wagner & Danks, 2009; Das et al., 2009;
Reynolds, 2003; Maris, 2010). The SH-SY5Y human neuroblastoma cell line is known to
undergo extensive differentiation in response to retinoic acid treatment (Encinas et al.,
2002; Thiele et al., 1991; Clagett-Dame et al., 2006; Das et al., 2009; Melino et al., 1997).
Retinoic acid has been shown to upregulate Cx43 (Vine & Bertram, 2005; Stahl & Sies,
1998; Long et al., 2010), however there have been no reports on its effect on the neuronal
connexins, Cx36 and Cx45. Therefore, the effect of retinoic acid on these neuronal
connexins was investigated in the SH-SY5Y neuroblastoma cell line. As expected,
markers of differentiation such as neurite outgrowth and Gap43 expression were
upregulated in response to retinoic acid treatment. In addition, Cx36 was transcriptionally
upregulated in response to retinoic acid induced differentiation, whereas Cx45 expression
levels did not increase in differentiating cells. Therefore, Cx36 appears to be downstream
of retinoic acid signaling, since it is upregulated upon retinoic acid induced
differentiation and Cx36 contains a retinoid X receptor binding motif similar to that of the
Cx43 gene (Cicirata et al., 2000). Conversely, Cx45 does not appear to be regulated by
retinoic acid. Thus, 1 have identified a potential transcriptional target, Cx36, in retinoic
acid signaling. In addition, since Cx36 expression increased upon retinoic acid induced
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differentiation, Cx36 gene expression was manipulated to ascertain its effects on
differentiation and proliferation of SH-SY5Y cells.

2.4.2 Cx36 Negatively Regulates SH-SY5Y Cell Differentiation
SH-SY5Y cells stably transfected with either EGFP or Cx36 were induced to
differentiate with retinoic acid treatment. EGFP expressing cells formed neurites within
two days of differentiation and formed extensive neurite networks by ten days.
Interestingly, Cx36 overexpressing cells formed sparse neurites by two and four days of
differentiation treatment. At ten days of differentiation, Cx36 overexpressing cells
formed limited neurite networks, indicated by decreased neurite density, compared with
EGFP expressing cells. Cx36 overexpressing cells also experienced diminished Gap43
and NPY transcript expression in response to differentiation treatment.
Conversely, SH-SY5Y cells stably expressing Cx36 shRNA projected neurites
within four days of differentiation treatment and formed extensive neurite networks
within ten days of differentiation. Cx36 knockdown resulted in significantly increased
neurite density compared to non-effective shRNA expressing cells. In addition,
knockdown of Cx36 resulted in increased Gap43 transcript and protein levels in response
to retinoic acid. Cx36 knockdown also resulted in increased Gap43 protein expression in
untreated cells. It was also observed that Cx36 shRNA expressing cells had increased
levels of NPY transcript prior to treatment and following ten days of differentiation
treatment.
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Cx36 appears to negatively regulate differentiation of SH-SY5Y human
neuroblastoma cells. Accordingly, knockdown of Cx36 enhances differentiation. This
appears to be in contradiction with the upregulation of Cx36 upon retinoic acid induced
differentiation. However, since I was unable to measure protein expression, it is possible
that although Cx36 mRNA is upregulated in response to retinoic acid, Cx36 protein
expression is unaffected. However, this discrepancy may be due to the requirement of an
optimal level of Cx36 for proper differentiation. Accordingly, the small increase in Cx36
expression induced by retinoic acid in wild-type cells does not appear to interfere with
differentiation.

However,

since

Cx36

overexpressing

cells

exhibit

diminished

differentiation and Cx36 knockdown enhances differentiation, it is apparent that
substantial changes in Cx36 expression alter the process of differentiation.
The effect of Cx36 on differentiation is in contrast to other connexins, which are
known to enhance differentiation (Vinken et al, 2006; Asazuma-Nakamura et al., 2009;
Banks et al., 2007; Brehm et al., 2007; Churko et al., 2010; Mao et al., 2000). For
example, overexpression of Cx43 and Cx32 enhanced nerve growth factor induced
differentiation of PC 12 cells (Belliveau et al., 2006). Although connexin overexpression
usually enhances differentiation, Todorova et al (2008) have shown that GJIC and Cx43
are required to maintain pluripotency of embryonic stem cells. Inhibition of GJIC or
Cx43 knockdown resulted in reduced proliferation and stem cell marker expression, with
a concomitant increase in differentiation marker expression (Todorova et al., 2008).
Thus, in certain environments, as with my Cx36 overexpression study, connexin
expression is required to maintain the stem cell phenotype. My finding of Cx36
knockdown enhancing differentiation in fact parallels the natural expression patterns of
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Cx36, where it is highly expressed in many neural structures of the developing fetus but
is subsequently downregulated during postnatal differentiation and maturation of the
nervous system (Belluardo et al., 2000; Gulisano et al., 2000). This downregulation may
be due in part to replacement of electrical synapses with chemical synapses (Lee et al.,
2010), or it may indicate that Cx36 is actually detrimental in the process of terminal
differentiation of certain structures, as was shown in this study.

2.4.3 Cx36 Promotes Clumping of SH-SY5Y Cells
A surprising finding was that altering Cx36 expression dramatically changed the
adhesion and aggregation properties of SH-SY5Y cells. EGFP expressing cells formed
large aggregates similar to wild-type cells following growth on collagen over ten days.
Interestingly, Cx36 overexpressing cells did not form these large adherent aggregates. In
contrast, Cx36 overexpressing cells formed small cell clumps. These clumps did not
adhere well to the dish, and were susceptible to lifting from the dish and growing in
suspension. This type of growth is similar to that of neurospheres, which are suspended
clusters of neural stem cells (Bez et al., 2003). In fact, it is characteristic of the neuroblast
subpopulations of SH-SY5Y cells to aggregate, lift off, and grow in suspension (Ross et
al., 1983; Biedler et al., 1978). Interestingly, this neuroblastic phenotype appears to be
stimulated by overexpression of Cx36, which is in accordance with my findings of Cx36
induced downregulation of differentiation.
Non-effective shRNA expressing cells formed large aggregates in a manner
similar to wild-type and EGFP expressing cells, however, Cx36 shRNA expressing cells
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did not form aggregates of any type when grown on collagen. Rather, knockdown of
Cx36 resulted in a dispersed phenotype with some neuritogenesis. This is in contrast to
non-effective shRNA expressing cells which extend few or no neurites.
NCAM and N-cadherin expression were assessed as potential mediators of the
differential aggregate formation in Cx36 overexpressing and knockdown cells. Cx43 is
known to colocalize with N-cadherin and regulate its localization at the cell surface (Wei
et al., 2005). Although there have been no documented reports of Cx36 and N-cadherin
interaction, I investigated whether manipulation of Cx36 expression resulted in changes
to N-cadherin expression. There was no difference between EGFP and Cx36 expressing
cells in N-cadherin protein expression. Non-effective shRNA and Cx36 shRNA-1
expressing cells also did not differ in N-cadherin protein expression. In addition, I
explored the effect of Cx36 expression on NCAM mRNA expression, as NCAM is
upregulated in poorly differentiated and aggressive neuroblastomas (Jensen & Berthold,
2007; Bourne et al., 1991). NCAM mRNA expression was not significantly altered with
Cx36 overexpression, however NCAM expression was reduced in Cx36 knockdown cells
compared with differentiating non-effective control. Therefore, although NCAM may be
mediating some of the adhesion properties related to cell aggregation, from this study, it
is most likely not the primary adhesion molecule involved in this process as it was
unaffected by Cx36 overexpression. While Cx36 expression has a dramatic effect on cell
aggregation, the adhesion molecules mediating this process are yet to be identified.
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2.4.4 Cx36 Increases Cell Proliferation
There is a substantial linkage between connexin expression and cell growth and
proliferation (Vinken et al., 2006; Kardami et al., 2007). My findings, however, were
unexpected as Cx36 overexpression increased cell proliferation, while knockdown of
Cx36 diminished cell proliferation. This is in contrast to other connexins which typically
act as tumor suppressors, specifically by inhibiting proliferation of tumor cells (Mao et
al., 2000; McLachlan et al., 2006; Jiminez et al., 2006; Omori et al., 2001; Zhang et al.,
1998). However, in certain environments, connexins and gap junctional intercellular
communication are required to maintain the proliferative ability of cells. For example,
extravillous trophoblasts lost the ability to proliferate when GJIC was inhibited by a gap
junction blocker or Cx40 antisense cDNA (Nisimura et al., 2004).
Additionally, Cx36 has been implicated in retinal cell survival following injury
(Striedinger et al., 2005). In light of the role of Cx36 in cell survival and its high
expression during development when neural precursors are proliferating, it is not
surprising to find that Cx36 serves to increase proliferation. It is also important to
consider that Cx36 is regulated in a different manner from other connexins. For example,
Cx36 channels show differential pH gating and experience very low sensitivity to voltage
gating (Gonazelz-Nieto et al., 2008; Srinivas et al., 1999). Specifically, Cx36 channels
close in response to alkalosis and open slightly in response to acidosis (Gonazelz-Nieto et
al., 2008). This pH gating may be important under pathological conditions such as
ischemia, where Cx36 expression has been shown to be upregulated and involved in cell
survival (Oguro et al., 2001). Therefore, the differential regulation mechanisms of Cx36
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channels may suggest a different role for Cx36 in key cellular processes from that of
other connexins.
In relation to differentiation, as neurons do not retain a capacity to divide, cells
must exit the cell cycle and stop proliferating in order to terminally differentiate into
neurons. Retinoic acid also exerts part of its differentiation inducing effects by inhibiting
cell proliferation (Voigt & Zintl, 2003). Therefore, the enhanced differentiation observed
in Cx36 shRNA expressing cells may be partially due to their decreased proliferative
ability.
This study is the first to determine the effects of Cx36 in the process of
differentiation. I have identified Cx36 as a novel potential transcriptional target of
retinoic acid signaling. However, further research is required to determine whether Cx36
is a direct target of retinoic acid signaling. In addition, Cx36 appears to negatively
regulate differentiation, which is in contrast to the effects of other connexins on
differentiation. Furthermore, it appears that Cx36 promotes a neural stem cell like
phenotype based on the diminished differentiation, enhanced clustering and increased
proliferation in overexpressing cells, and the reversal of this phenotype in cells where
Cx36 is knocked down.
However, it is unknown whether Cx36 mediates these changes in a gap junctional
intercellular communication dependent manner or through interaction of Cx36 with
binding partners, and therefore downstream signaling pathways. Therefore, further
research is required to elucidate the mechanisms underlying the regulation of
differentiation by Cx36.
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3.1 Summary and Conclusions
Objective One: Determine the changes in connexin gene expression following retinoic
acid induced differentiation o f neuroblastoma
Cx43 is known to be upregulated in response to retinoic acid (Stahl & Sies, 1998;
Vine & Bertram, 2005; Long et a l, 2010). However, the effect o f retinoic acid treatment
on Cx45 and Cx36 has not been explored. In this study, I investigated whether Cx45 or
Cx36 were involved in retinoic acid signaling. Retinoic acid treated cells formed neurites
and had increased levels of the differentiation marker, Gap43. Cx45 expression did not
increase in retinoic acid treated cells. Conversely, Cx36 mRNA expression was
upregulated in response to retinoic acid treatment, indicating that Cx36 may be a target of
retinoic acid signaling.

Objective Two: Investigate the effects o f Cx36 overexpression on differentiation and
proliferation o f human neuroblastoma cells
Although many connexins have been shown to regulate differentiation and
proliferation, the effect of Cx36 on these processes has not been explored. EGFP and
Cx36 were stably transfected in SH-SY5Y human neuroblastoma cells. Cx36
overexpressing cells had diminished neuritogenesis in response to retinoic acid and
BDNF differentiation treatment. These differentiated cells also had decreased expression
of differentiation markers, Gap43 and NPY. Interestingly, untreated Cx36 overexpressing
cells formed abundant clumps when grown on collagen. These cells were also susceptible
to lifting from the dish and growing in suspension. Conversely, EGFP expressing cells
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formed large, adherent aggregates on collagen. In addition, Cx36 overexpressing cells
were more proliferative than EGFP expressing cells. Thus, overexpression of Cx36
diminishes neuronal differentiation and promotes cell clumping and proliferation.

Objective Three: Investigate the effects o f knocking down Cx36 on differentiation and
proliferation o f human neuroblastoma cells
SH-SY5Y human neuroblastoma cells were stably transfected with non-effective
shRNA, or shRNA targeting Cx36. Cx36 shRNA expressing cells had enhanced
neuritogenesis in response to differentiation treatment. In addition, differentiated cells
expressed higher levels of Gap43 and NPY. Cx36 shRNA expressing cells exhibited a
dispersed morphology when grown on collagen and rarely formed clumps or aggregates.
Finally, Cx36 shRNA expressing cells had decreased proliferation compared to non
effective shRNA expressing cells. Therefore, knockdown of Cx36 promotes neuronal
differentiation and decreases cell proliferation and aggregation.

3.2 Contributions of the Research
3.2.1 General Significance
Cx36 is one of the most recently discovered members of the connexin family
(Belluardo et al., 1999; Sohl et al., 1998). The Cx36 literature is heavily focused on
spatial and temporal expression analysis, as well as some trafficking and channel function
studies (Srinivas et ah, 1999; Gulisano et ah, 2000; Zoidl et ah, 2002; Gonzalez-Nieto et
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al., 2008; Wellerhaus et al., 2008). Therefore, I investigated the effect of manipulating
Cx36 expression on neuronal differentiation. In this study, I identified Cx36 as a novel
potential target of retinoic acid signaling. In addition, Cx36 was found to act as a
negative regulator of neuronal differentiation. This study is the first to explore the effects
of manipulating Cx36 expression levels to investigate the process of differentiation. Since
most connexins enhance differentiation and suppress proliferation (Temme et al., 1997;
Zhang et al., 1998; Belliveau et al., 2006; Jimenez et al., 2006;), it would be intriguing to
determine which distinguishing characteristic of Cx36 leads to its unique effects on these
cellular processes.

3.2.2 Cx36 Negatively Regulates Differentiation of SH-SY5Y Cells
Cx36 overexpressing cells exhibited diminished neuritogenesis as well as Gap43
and NPY expression in response to retinoic acid treatment, whereas Cx36 shRNA
expressing cells displayed enhanced neuritogenesis and Gap43 and NPY expression in
response to retinoic acid. Cx36 shRNA-4 did not have an effect on Gap43 expression,
however this was most likely due to the lower knockdown efficiency of this shRNA.
These studies have revealed Cx36 as a down-regulator of differentiation, while
knockdown of Cx36 enhances differentiation. As stated in Section 3.2.1, this corresponds
to the temporal expression patterns of Cx36. In the adult brain Cx36 is expressed in many
structures including the inferior olive, olfactory bulb, retina, and hippocampus (Gulisano
et al., 2000; Belluardo et al., 2000; Weickert et al., 2005; Placantonakis et al., 2006; Pan
et al., 2010). Cx36 is highly expressed in the first two postnatal weeks in many neuronal
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structures, including the spinal cord, ventral thalamic nuclei and the majority of the
cerebral cortex. However, these structures either lose or limit Cx36 expression to specific
subregions following the second postnatal week (Belluardo et al, 2000). In light of my
findings, potentially detrimental effects of Cx36 on differentiation of certain structures
may necessitate the tight temporal regulation of Cx36 expression.

3.2.3 Cx36 Promotes Cell Clumping
Unexpectedly, Cx36 overexpressing cells formed numerous small clumps when
grown on collagen, whereas EGFP expressing cells grew to form large adherent
aggregates. The clumps formed by Cx36 overexpressing cells were prone to lifting off the
dish and growing in suspension in a manner similar to neural progenitor cells that form
neurospheres (Bez et al., 2003). Conversely, SHSY-5Y cells expressing Cx36 shRNA did
not form aggregates on collagen, and rather, maintained a dispersed phenotype.
It appears that Cx36 may regulate the expression of one or more adhesion
molecules involved in both cell-matrix and cell-cell adhesion. The cell-matrix adhesion
would influence the ability of the cells to lift off and grow in suspension, while cell-cell
adhesion would mediate their ability to form clumps or aggregates. Both N-cadherin and
neural cell adhesion molecule (NCAM) mediate cell-cell adhesion. Since Cx43 is known
to regulate N-cadherin localization, the effect of Cx36 overexpression and knockdown on
N-cadherin expression was investigated (Wei et al., 2005). However, manipulation of
Cx36 expression did not result in changes in N-cadherin protein expression. NCAM is
associated with aggressive and poorly differentiated neuroblastoma tumors (Jensen &
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Berthold, 2007; Bourne et al., 1991), and thus its expression was also examined in
response to Cx36 expression manipulation. NCAM mRNA expression did not change in
response to Cx36 overexpression, however it was decreased in Cx36 shRNA expressing
cells. The NCAM protein has three different isoforms due to alternative splicing and a
post-translational modification to incorporate polysialic acid, which is the form that is
associated with the aggressive cancer phenotype (Jensen & Berthold, 2007). Since
NCAM protein expression was not assessed, I cannot conclude with certainty that it is not
a mediator of the clumping effect seen in Cx36 overexpressing cells. Therefore, although
there is an obvious change in clumping and aggregation in response to manipulating
Cx36 expression, the adhesion molecule involved in this process has yet to be identified.

3.2.4 Cx36 Increases Proliferation of SH-SY5Y Cells
In addition to its effect on differentiation and aggregation, Cx36 also regulates
proliferation. Cx36 overexpression in SH-SY5Y cells increased cell proliferation, while
knockdown of Cx36 reduced proliferation. As with the effect of Cx36 on differentiation,
this result is in accordance with the high expression of Cx36 during early postnatal
development when neural cells are proliferating. In adulthood, neurons do not divide, and
thus downregulation of Cx36 may be necessary to exit the cell cycle. In addition, Cx36
promotes cell survival in retinal cells following injury and in the hippocampus during
ischemia (Oguro et al., 2001; Striedinger et al., 2005; Orellana et al., 2009). In light of
my results, it is likely that Cx36 promotes cell proliferation in addition to its established
role in cell survival.
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3.3 Limitations and Future Studies
3.3.1 Limitations of In Vitro Model
My studies were limited to the SH-SY5Y neuroblastoma cell line. Unfortunately,
these cells were unsuitable for immunocytochemical uses. Cells aggregated on glass
coverslips and permanox chamber slides and lifted off the slides during washing or
fixing. In addition, the remaining cells exhibited disrupted cell morphology. Several
different fixatives were applied, however only one of these maintained the integrity of the
cells: 2% paraformaldehyde supplemented with 150 mM sodium chloride, 120 mM
sucrose, and 0.1% glutaraldehyde. However, even this fixative resulted in few cells
remaining on the coverslip and inconsistent labelling, and thus immunocytochemical
studies were abandoned. Immunocytochemistry would have allowed me to assess the
localization patterns of endogenous Cx36, as well as the effects of Cx36 overexpression
and knockdown on its localization. Furthermore, the effect of Cx36 on the subcellular
localization patterns of N-cadherin could have been investigated, as the effect of Cx43 on
N-cadherin is on localization rather than expression (Wei et al., 2005).
SH-SY5Y cells had intermediate expression levels of Cx36 and thus allowed for
both overexpression and knockdown studies. However, only a single cell line was utilized
and therefore I cannot generalize to other cell lines or tissues. Originally, I had the use of
three neuroblastoma cell lines, however, due to unsuccessful transfection and
differentiation, I could not pursue my studies with the other cell lines. This study would
benefit from the use of additional neuroblastoma cell lines, especially retinoic acid
responsive and MYCN amplified cell lines, such as LAN-5 and SK-N-BE (Negroni et ah,
1991; Cervello et ah, 2000; Suenaga et ah, 2009). In addition, it would be ideal to analyze
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human neuroblastoma tumor samples for Cx36 expression at various stages of
differentiation. Furthermore, assessing Cx36 expression in the transgenic mouse model
that spontaneously develops neuroblastoma would supplement my work at the cellular
level with tissue, and thus ensure the generalizability of my studies (Weiss et al., 1997).

3.3.2 Cx36 Expression Analysis Tools
Cx36 is a relatively recently discovered connexin, thus limiting the availability of
reliable antibodies for its detection by western blot. Several antibodies were tested
including Zymed 366400, which is the most cited Cx36 antibody in the literature (Li et
al., 2004a,b; Rezende et al., 2007; Helbig et al., 2010). However, none of these antibodies
provided a consistently detectable signal, despite the use of several different cell lysis
buffers. Two custom polyclonal antibodies were then designed; one was targeting the
carboxy terminus and the other targeting the cytoplasmic loop. However, neither of these
antibodies has provided consistent detection when both positive and negative control
tissues were included for testing. Further characterization of these antibodies is required.
At this point, however, real-time PCR is the most consistent and reliable method of Cx36
expression analysis. This method only detects transcript levels, which is usually but not
always correlated with protein expression (Guo et al., 2008). The knockdown studies
would have greatly benefited from Cx36 protein expression data due to my inconsistent
detection of the Cx36 transcript. shRNA knockdown inhibits translation by targeting the
transcript for the protein of interest for degradation (Paddison et al., 2002). However, in
real-time PCR, the amplicon is very small (less than 200bp long), and thus a region of the
transcript that has not been degraded may be amplified and mask the effect of the shRNA

96
knockdown (Shepard, Jacobson & Clark., 2005; Holmes et al., 2010). Therefore it would
be ideal to quantify Cx36 expression at the protein level; however this is not feasible with
the currently available antibodies.

3.3.3 Future Studies
Although 1 have identified Cx36 as a potential target of retinoic acid signaling, it
is yet to be determined whether this occurs through a direct mechanism. I would
undertake either o f two approaches in order to determine whether Cx36 is a direct
transcriptional target of retinoic acid. Transfection of cells with a plasmid encoding the
promoter region of Cx36 and the firefly luciferase reporter, followed by measuring
reporter activity after retinoic acid treatment would demonstrate that Cx36 is directly
regulated by retinoic acid. Alternatively, adding retinoic acid following treatment with
the protein synthesis inhibitor, cycloheximide, and detecting Cx36 upregulation within
four hours would indicate that Cx36 is a direct target of retinoic acid. Either of these
experiments would allow me to determine whether there is a direct interaction between
retinoic acid and Cx36 expression.
The most immediate concern involves determining the identity of the adhesion
molecules that are regulated by Cx36. N-cadherin and NCAM are unlikely to be the
primary facilitators of the clumpy and dispersed phenotype exhibited by Cx36
overexpressing and knockdown cells respectively. Integrin beta 1 and CD 147 are other
possible candidates that are involved in differentiation and cell aggregation (Rozzo,
Chiesa & Ponzoni, 1997; Garcia et al., 2009). The intregrins are prime candidates since
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they are responsible for cell-matrix adhesion and Cx36 overexpressing cells appear to be
compromised in their ability to adhere to collagen-coated culture dishes. However further
studies must be conducted to determine whether expression patterns of these adhesion
molecules are altered by Cx36 manipulation.
Furthermore, due to the immature phenotype of Cx36 overexpressing cells,
including increased proliferation and clustering as well as decreased cell differentiation,
these cells may be reverting to a more progenitor cell phenotype. To further explore this
possibility, Notch and Inhibition of Differentiation/ DNA binding 2 (ID2) expression
should be investigated (Ferrari-Toninelli et al., 2009; Lopez-Carballo et al., 2002). Notch
is a stem cell marker that has been implicated in neuroblastoma. Notch activation results
in morphological remodeling of differentiated cells and its inhibition results in growth
arrest and increased differentiation of SH-SY5Y cells (Ferrari-Toninelli et al., 2009;
Ferrari-Toninelli et al., 2010). In addition, ID2 is expressed in neural crest cells and is
also known to increase proliferation and inhibit differentiation of neuroblastoma cells
(Lofstedt et al., 2004). ID2 is a transcriptional target of MYCN and is highly expressed in
MYCN amplified neuroblastoma cell lines (Lasorella et al., 2000; Lasorella et al., 2002).
Therefore, since Notch and ID2 are highly expressed in the neural crest and in
dedifferentiated neuroblastoma cells, it would be of interest to ascertain whether Cx36
overexpression upregulates these markers.
The Cx36 and Cx50 specific channel blocker, mefloquine, or dominant-negative
mutant of Cx36 could be used to supplement the shRNA knockdown component of this
study (Allison et al., 2006; Cruikshank et al., 2004). In particular, if mefloquine has the
same effect on differentiation as the knockdown, it would suggest a gap junction
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intercellular communication dependent function of Cx36. Conversely, if mefloquine
successfully blocks Cx36 channel function without effecting differentiation then I may
conclude that knockdown of Cx36 has a GJIC independent effect on differentiation. In
this event, to further elucidate the mechanism behind the effect of Cx36 on
differentiation, the impact of transfecting a dominant negative mutant in wild type (WT)
and Cx36 overexpressing cells would be investigated. The dominant negative mutant of
Cx36 blocks WT Cx36 from trafficking to the plasma membrane and prevents GJIC in
multiple cell types (Placantonakis, Cicirata & Welsch, 2002). If the mutant has similar
effects to Cx36 shRNA, I may conclude that the effect of Cx36 on differentiation is due
to its interaction with binding partners. The interaction of Cx36 with known binding
partners occurs during trafficking to the cell membrane or at the cell membrane itself (Li
et al., 2004a, b; Li et al., 2009), thus this interaction would be limited since the mutant
prevents Cx36 trafficking and traps it intracellularly.
The SH-SY5Y human neuroblastoma cell line is not MYCN amplified (Edsjo et
al., 2003). It would be of interest to broaden my studies to include other human
neuroblastoma cell lines that are retinoic acid responsive and MYCN amplified, such as
the LAN-5 and SK-N-BE cell lines (Negroni et al., 1991; Cervello et al., 2000; Suenaga
et al., 2009). In particular, this will allow us to determine whether manipulation of Cx36
expression has an effect on MYCN expression, and whether Cx36 knockdown has a
stronger effect on differentiation and proliferation in a more aggressive and less
differentiated neuroblastoma cell line.
In addition, in order to take this study another step forward, the effect of Cx36 on
the tumor cell phenotype should be investigated. For example, the migration, invasion,
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and anchorage independent growth properties of Cx36 overexpressing and knockdown
cells should be studied. The anchorage independent growth studies would be of particular
interest due to the clumping and growth in suspension of Cx36 overexpressing cells. To
assess differences in tumorigenicity, Cx36 overexpressing and knockdown cells along
with their respective controls could be subcutaneously injected into athymic (Balb/c
nude) mice to evaluate the sizes of the tumors formed (Zhao et al., 2008).
As mentioned in Section 3.3.1, analysis of murine or human tumor samples would
allow us to broaden the implications of my work from the cellular to the tissue and
organism level. Based on my results, it would be interesting to determine whether Cx36
is more highly expressed in less differentiated and therefore, more aggressive
neuroblastoma tumors. The Weiss Laboratory has been contacted regarding murine
samples, however we are still awaiting a response (Weiss et ah, 1997). We are also
currently preparing a proposal to acquire human patient samples from the Children’s
Oncology Group.
Finally, the susceptibility of Cx36 overexpressing and knockout mice to
chemically induced tumorigenesis could be explored in the future. Cx43 and Cx32
knockout mice are prone to chemically induced tumorigenesis (Temme 1997; King &
Bertram, 2005). However, since Cx36 knockdown at the cellular level results in enhanced
differentiation and suppressed proliferation, it is more likely that Cx36 overexpressing
mice are more susceptible to chemically induced tumorigenesis. Unfortunately, although
Cx36 knockout mice are available (Deans et ah, 2001; Guldenagel et ah, 2001), Cx36
overexpressing mice have not been generated. Thus, this study must wait until the
necessary tools become available.
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This is the first study to report the effects of manipulating Cx36 expression on
cellular processes such as differentiation and proliferation. Thus, it provides a baseline
from which to expand into other processes including the hallmarks of cancer, such as
migration, invasion, anchorage independent growth and tumorigenicity. Furthermore, the
use of animal models would also expand this study from the cell to the tissue and
organism level. In conclusion, while this study provides an insight into the effect of Cx36
on key cell processes, it remains a novel area of research open to further investigation.
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Figure A .l. C x36 overexpression is maintained over ten days of differentiation
treatment.
RNA was isolated from cells at day 0, 2, 4, and 10 of treatment, and real-time
PCR was used to quantify mRNA expression. Cx36 mRNA expression was
significantly higher in Cx36 overexpressing cells at day 0 and 10 in untreated
cells, and days 2, 4, and 10 in treated cells. mRNA levels were normalized to
PPIA mRNA. *p< 0.05. N=3. Bars show mean +/- S.E.

Figure A.2. NCAM and N-cadherin expression were not altered in differentiating
Cx36 overexpressing cells.
RNA and protein isolated from cells at day 0 and 10 of treatment, and real-time
PCR was used to quantify mRNA expression and western blotting to quantify
protein expression. NCAM mRNA expression levels were not significantly
different between any condition (A). N-cadherin protein expression levels did not
change between differentiation treatment or overexpression conditions (B & C).
mRNA levels were normalized to PP1A mRNA and protein levels to GAPDH.
N=3. Bars show mean +/- S.E.
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Figure A.3. NCAM expression was reduced in Cx36 shRNA expressing cells and Ncadherin expression was only decreased in shRNA-4 expressing cells.
RNA and protein were isolated from cells at day 0 and 10 of differentiation
treatment, and real-time PCR was used to quantify mRNA expression and western
blots to quantify protein expression. NCAM mRNA expression was higher in
treated non-effective control cells than all other conditions (A). N-cadherin
protein expression levels were decreased in shRNA-4 but not shRNA-1
expressing cells in comparison to non-effective control (B & C). mRNA levels
were normalized to PPIA mRNA and protein levels to GAPDH. *p< 0.05. N=3.
Bars show mean +/- S.E.
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